

REFERENCE

- 1- ***Alain C Masquelet and Leon Dorn, (2005):*** Anatomy of Intestine in Atlas of Surgical Anatomy 2nd ed, Chap 5, Pp: 106-115. Edited by Rayan J and Leon Dorn. Pa: Taylor and Frqancis.
- 2- ***Al-Akwaa AM, Siddiqui N, Al-Mofleh IA, (2004):*** Primary gastric lymphoma. World J Gastroenterol; 10:5–11.
- 3- ***Al Sheneber J and Shibata H (1997):*** Primary gastric lymphoma. Cancer control: JMCC: 4(3): 245-253.
- 4- ***Aleman BM, Haas RL, van der Maazen RW., (2010):*** Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Best Pract Res Clin Gastroenterol; 24:27–34.
- 5- ***Arends JE, Bot FJ, Gisbertz IA, Schouten HC., (1999):*** Expression of CD10, CD75 and CD43 in MALT lymphoma and their usefulness in discriminating MALT lymphoma from follicular lymphoma and chronic gastritis. Histopathology; 35:209–15.
- 6- ***Ashton-Key M., Diss T.C. and Isaacson P.G., (1996):*** Analysis of shallow ulcers in ulcerative jejunitis and enteropathy associated T-cell lymphoma. Mod Pathol 9: 106A.
- 7- ***Baens M, Maes B, Steyls A., (2000):*** The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol; 156: 1433-9.
- 8- ***Bayerdorffer E, Neubauer A, Morgner A, et al., (2003):*** Regression of primary gastric low-grade MALT lymphoma after cure of Helicobacter pylori infection—German MALT lymphoma trial. Gastroenterology; 110:A490.

- 9- **Bienenstock J, Ernst PB, underdown BJ., (1997):** The gastrointestinal tract as an immunologic organ – state of the art. *Ann Allergy*; 59:17-20.
- 10- **Brazier RM, arber DA, Slovak ML, et al., (2009):** The Burkitt-like lymphomas: a southwest Oncology Group study delineating phenotypic, genotypic and clinical features. *Blood*; 97:3713-20.
- 11- **Breslow NE and Day NE, (1999):** Unconditional logistic regression for large strata. In: *The Analysis of Case-control Studies, Statistical Methods in Cancer Research*, vol. 1, Davis W (ed.) pp 192–247, International Agency for Research on Cancer: Lyon.
- 12- **CalettiG, Fusaroli P, Togliani T, Bocus P, Roda E., (2007):** Endosonography in gastric lymphoma and large gastric folds. *Eur J Ultrasound* 11: 31-40.
- 13- **Carol E.H, Scott Conner, and David L. Dawson, (2009):** Small and Large Intestine In: *Operative Anatomy* 3rd ed, Chap 4Pp; 876-891. Edited by Harry J and Scott Conner. Pa: Lippincott Williams & Wilkins.
- 14- **Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, et al., (2007):** Revised response criteria for malignant lymphoma. *J Clin Oncol*; 25:579–586.
- 15- **Chou CK, Chen LT, Sheu RS, Yang CW, Wang ML, Jaw TS, Liu GC., (2009):** MRI manifestations of gastrointestinal lymphoma. *Abdom Imaging*; 19:495–500.
- 16- **Chung HH, Kim YH, Kim JH, Cha SH, Kim BH, Kim TK, Kim AR, Cho SJ., (2008):** Imaging findings of mantle cell lymphoma involving gastrointestinal tract. *Yonsei Med J*; 44:49–57.

- 17- **Crump M, Gospodarowicz M, Shepherd FA., (2007):** Lymphoma of the gastrointestinal tract. *Semin Oncol*; 26:324–37.
- 18- **D’Elios MM, Amedei A, Manghetti M., (1999):** Impaired T-cell regulation of B-cell growth in *Helicobacter pylori*-related gastric low-grade MALT lymphoma. *Gastroenterology*; 117: 1105-12.
- 19- **D’Amore F, Brincker H, Gronbaek K, et al., (1994):** Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. *J Clin Oncol.*; 12:1673-1684.
- 20- **De Wolfe- Peeters C and Tierens A., (2003):** Controversies in MALT lymphoma classification, low and high grade. *Histopatholgy*; 32: 277-278.
- 21- **Dickson BC, Serra S, Chetty R, (2006):** Primary gastrointestinal tract lymphoma: diagnosis and management of common neoplasms. *Expert Rev Anticancer Ther.*; 6:1609–1628.
- 22- **Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, De Wolf-Peeters C, Hagemeijer A, Van den Berghe H, Marynen P., (2000):** The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. *Blood*; 93: 3601-9.
- 23- **Dogan A, Du M, Koulis A., (1997):** expression of lymphocyte homing receptors and vascular addressins in low-grade gastric B-cell lymphomas of mucosa-associated lymphoid tissue. *Am J Pathol*; 151:1361-1369.

- 24- **Du, M., Peng, H., Singh, N., Isaacson, P.G., and Pan, L., (2000):** The accumulation of p53 abnormalities is associated with progression on mucosa-associated lymphoid tissue lymphoma. *Blood* 86: 4587-4593.
- 25- **El Bolkainy N (2000):** Topographic Pathology of cancer: National Cancer Institute. Cairo University 2000; Gastrointestinal cancer 29-42.
- 26- **Elstrom RL, Martin P, Leonard JP., (2008):** New biologic agents and immunologic strategies. *Hematol Oncol Clin North Am.*; 22:1037–1049, x-xi.
- 27- **Fagioli F, Rigolin G, Cuneo A et al (1998):** Primary gastric lymphoma: distribution and clinical relevance of different epidemiological factors. *Hematologica*; 79: 213-217.
- 28- **Ferreri AJ, Cordio S, Ponzoni M, Villa E., (2004):** Non-surgical treatment with primary chemotherapy, with or without radiation therapy, of stage I-II high-grade gastric lymphoma. *Leuk Lymphoma*; 33:531–41.
- 29- **Ghai S, Pattison J, Ghai S, O'Malley ME, Khalili K, Stephens M., (2007):** Primary gastrointestinal lymphoma: spectrum of imaging findings with pathologic correlation. *Radiographics*; 27:1371–1388.
- 30- **Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, Martínez A, Colomo L, Campo E, Montserrat E, et al., (2006):** The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. *Ann Oncol.*; 17:1539–1545.

- 31- **Gollub MJ., (2008):** Imaging of gastrointestinal lymphoma. *Radiol Clin North Am.*
- 32- **Gospodarowicz MK, Sutcliffe SB, Clark RM, et al., (2001):** Outcome analysis of localized gastrointestinal lymphoma treated with surgery and postoperative irradiation. *Int J Radiat Oncol Biol Phys.*; 19:1351-1355.
- 33- **Guindi M., (2000):** Role of activated host T cells in the promotion of MALT lymphoma growth. *Semin Cancer Biol*; 10: 341-4.
- 34- **Guili R(2001):** The primary gastric lymphoma: Definition. *J surg oncol.*
- 35- **Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC., (1994):** A revised European- American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. *Blood*; 84: 1361-1392.
- 36- **Harris, N.L., Ferry, J.A., and Swerdlow, S.H., (1997):** Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. *Semin Diagn Pathol* 14: 8-14.
- 37- **Hoster, Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM., (2008):** A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. *Blood*; 111(2):558-565.
- 38- **Iagaru A, Goris ML, Gambhir SS., (2008):** Perspectives of molecular imaging and radioimmunotherapy in lymphoma. *Radiol Clin North Am.*; 46:243–252, viii.

- 39- **Isaacson PG and Du MQ., (2005):** MALT lymphoma: from morphology to molecules. *Nat Rev Cancer*; 4: 644-53.
- 40- **Isaacson PG and Du MQ., (2004):** Gastrointestinal lymphoma: where morphology meets molecular biology. *J Pathol*; 205:255–274.
- 41- **Isaacson P.G., O'Connor N.T.J., and Spencer J., (1995):** Malignant histiocytosis of the intestine: a T-cell lymphoma. *Lancet* 2: 688-691.
- 42- **Isaacson P, Spencer J and Wright DH (2001):** Classifying primary gut lymphomas. *Lancet*, 2: 1148-9.
- 43- **Jaffe ES, Harris NL, Stein H, et al., (2001):** Tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press.
- 44- **Jaffe ES, Krenacs L, Kumar S, Kingma DW, Raffeld M., (1999):** Extranodal peripheral T-cell and NK-cell neoplasms. *Am J Clin Pathol*; 111: S46-S55.
- 45- **Kalaoka I, Arima F, Nishimoto J, Watanabe T, Kobayashi Y, Tamura R, Yamamoto S, Matsuno Y, Shimoda T and Tobinai K (2002):** Enteropathy type T-cell lymphoma showing repeated small bowel rupture and refractoriness to chemotherapy: a case report, *Jpn J clin Oncol*, 32:546-49.
- 46- **Kawahara Y, Yokota K, Mizuno M, Yunoki N, Uesu T, Okada H, Kobayashi K, Hirai Y, Oguma K, Tsuji T., (1999):** Antibodies to human gastric epithelial cells and heat shock protein 60 in *Helicobacter pylori* positive mucosa associated lymphoid tissue lymphoma. *Gut*; 45: 20-3.
- 47- **Kim YH, Lee JH, Yang SK, Kim TI, Kim JS, Kim HJ, Kim JI, Kim SW, Kim JO, Jung IK, et al., (2009):** Primary colon lymphoma in Korea: a KASID (Korean Association for the Study of Intestinal Diseases) Study. *Dig Dis Sci.*; 50:2243–2247.

- 48- **Koch P, del Valle F, Berdel WE, et al., (2006):** Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. *J Clin Onco*; 19:3861–3873.
- 49- **Kodera Y, Yamamura Y, Nakamura S, et al., (2005):** The role of radical gastrectomy with systematic lymphadenectomy for the diagnosis and treatment of primary gastric lymphoma. *Ann Surg* 227:45–50.
- 50- **Krol AD, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM., (2003):** Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. *Ann Oncol*. Jan; 14(1):131-9.
- 51- **Kropman RF and Blok P., (2002):** Disappearance of a mucosa-associated lymphoid tissue (MALT) lymphoma of the urinary bladder after treatment for *Helicobacter pylori*. *Eur J Haematol*; 68: 187-8.
- 52- **Lewin KJ, Ranchod M and Dorfman RF (2004):** Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. *Cancer*, 2:693-707.
- 53- **Liang R, Todd D, Chan TK, Chiu E, Lie A, Kwong YL, Choy D, Ho FC., (2002):** Prognostic factors for primary gastrointestinal lymphoma. *Hematol Oncol*; 13: 153-163.
- 54- **Liu H, Ye H and Ruskone-Fourmestraux A (2004):** T(11:18) is a marker for all stage gastric MALT lymphomas that will not respond to *H pylori* eradication. *Gastroenterology*, 122:1286-1294.

- 55- **Lupescu IG, Grasu M, Goldis G, Popa G, Gheorghe C, Vasilescu C, Moicean A, Herlea V, Georgescu SA., (2007):** Computer tomographic evaluation of digestive tract non-Hodgkin lymphomas. *J Gastrointestin Liver Dis*; 16:315–319.
- 56- **Mendelson RM and Fremoye S (2005):** Primary gastrointestinal lymphomas: a radiological-pathological review. Part 1: stomach, esophagus and colon. *Australas Radiol*, 49:353-364.
- 57- **Miyamoto M, Haruma K, Hiyama T, et al.,(2002):** High incidence of B-cell monoclonality in follicular gastritis: a possible association between follicular gastritis and MALT lymphoma. *Virchows Arch*; 440: 376-80.
- 58- **Montalban C., Manzanal A. and Boixeda D., (1997):** Helicobacter pylori eradication for the treatment of low grade gastric MALT lymphoma. Follow-up together with sequential molecular studies. *Ann. Oncol.*, 8(suppl.2): 37-9.
- 59- **Morgner A, Lehn N, Andersen LP, Thiede C, Bennedsen M, Trebesius K, Neubauer B, Neubauer A, Stolte M, Bayerdorffer E., (2000):** Helicobacter-associated primary gastric low-grade MALT lymphoma: Complete remission after curing the infection. *Gastroenterology*; 118: 821-8.
- 60- **Morrison VA., (2008)** Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma. *Expert Rev Anticancer Ther*; 8:1651–1658.
- 61- **Moynihan M.J., Bast M.A., Chan W.C., Delabie J., Wickert R.S., Wu G. and Weisenberger D.D., (2001):** Lymphomatous polyposis:

- a neoplasm of either follicular mantle or germinal center cell origin.
Am J Surg Pathol 20: 442-452.
- 62- **Musshoff K., (1999):** Clinical staging classification of non-Hodgkin's lymphomas. Strahlentherapie; 153: 218-221.
- 63- **Mustafa I, Clark J, Khorsand J et al (2003):** Gastric Lymphoma.
In: Wanebo HJ, (ed): Surgery for Gastrointestinal Cancer: A Multidisciplinary Approach (1st ed). Philadelphia: Lippincott-Raven: 371-379.
- 64- **Myung SJ, Joo KR, Yang SK, Jung HY, Chang HS, Lee HJ, Hong WS, Kim JH, Min YI, Kim HC, et al., (2007):** Clinicopathologic features of ileocolonic malignant lymphoma: analysis according to colonoscopic classification. Gastrointest Endosc; 57:343–347.
- 65- **Nakamura S, Matsumoto T, Jo Y, Fujisawa K, Suekane H, Yao T, Tsuneyoshi M, Iida M., (2003):** Chromosomal translocation t(11;18)(q21;q21) in gastrointestinal mucosa associated lymphoid tissue lymphoma. J Clin Pathol; 56: 36-42.
- 66- **Nakamura, S., Akazawa, K., Kinukawa, N., Takashi, Y, and Tsuneyoshi, M., (1999):** Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma. Hum Pathol 27: 225-233.
- 67- **Nicolaidis C, Fountzilas G, Zoumbos N et al., (1998):** Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non Hodgkin's Lymphoma Prognostic Index. Oncology (in press).
- 68- **Novackovic BJ, Novakovic S and Grazio SF (2006):** A single-center report on clinical feature and treatment response in patients with

- intestinal T-cell non-Hodgkin's lymphomas. *Oncol Report*, 16:191-95.
- 69- **Ogura M., (2010):** Current treatment strategy and new agents in mantle cell lymphoma. *Int J Hematol.*; 92:25–32.
- 70- **Oken MM, Creech RH, Tormey DC, et al., (1982):** "Toxicity and response criteria of the Eastern Cooperative Oncology Group". *Am. J. Clin. Oncol.* 5 (6): 649–55.
- 71- **Paoluzzi L, Kitagawa Y, Kalac M, Zain J, O'Connor OA., (2008):** New drugs for the treatment of lymphoma. *Hematol Oncol Clin North Am.*; 22:1007–1035.
- 72- **Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsis V, Fountzilas G, Pavlidis N, Dimopoulos M, Tsatalas C, Xiros N, Economopoulos T. (2006):** Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG) *Leuk Lymphoma*; 47:2140–2146.
- 73- **Paulson S, Sheehan RG, Stone MJ, et al, (1999):** Large cell lymphomas of the stomach: improved prognosis with complete resection of all intrinsic gastrointestinal disease. *J Clin Oncol*; 263-269.
- 74- **Pennazio M., (2008):** Small-intestinal pathology on capsule endoscopy: spectrum of vascular lesions. *Endoscopy*; 37:864–869
- 75- **Peterson WL, Fendrick AM, Cave DR, et al., (2003):** *Helicobacter pylori*-related disease: guidelines for testing and treatment. *Arch Intern Med*; 160:1285–91.
- 76- **Ponzoni M, Ferreri AJ, Pruneri G, Pozzi B, Dell'Oro S, Pigni A, Pinotti G, Villa E, Freschi M, Viale G, et al., (2003):** Prognostic

- value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome. *Int J Cancer*; 106:288–291.
- 77- **Rabbi C, Aitini E, Cavazzini G, et al., (2006):** Stomach preservation in low- and high-grade primary gastric lymphomas: preliminary results. *Haematologica*; 81:15–9.
- 78- **Radan L, Fischer D, Bar-Shalom R, Dann EJ, Epelbaum R, Haim N, Gaitini D, Israel O., (2010):** FDG avidity and PET/CT patterns in primary gastric lymphoma. *Eur J Nucl Med Mol Imaging*; 35:1424–1430.
- 79- **Radaszkiewicz T, Dragosics B, Bauer P., (2002):** Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. *Gastroenterology*; 102:1628–38.
- 80- **Rotterdam H., and Tsang P., (2002):** Gastrointestinal disease in the immunocompromised patient. *Hum Pathol* 25: 1123-1140.
- 81- **Ruland J, Duncan GS, Elia A, del Barco Barrantes I, Nguyen L, Plyte S, Millar DG, Bouchard D, Wakeham A, Ohashi PS, Mak TW., (2001):** Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. *Cell*; 104: 33-42.
- 82- **Schechter N and Yahalom J (2000):** Low-grade MALT Lymphoma of the stomach: a review of diagnosis and treatment options. *Int J Radiation Oncol Biol Phy*:40(5): 1095-1103
- 83- **Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM., (2007):** The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for

- patients with diffuse large B-cell lymphoma treated with R-CHOP. *Blood*. Mar 1; 109(5):1857-61.
- 84- **Seifert E, Schulte F, Weismuller J, et al., (2003):** Endoscopic and bioptic diagnosis of malignant non-Hodgkin's lymphoma of the stomach. *Endoscopy*; 25:497–501.
- 85- **Shchepotin IB, Evans SR, Shabahang M, et al., (1996):** Primary non-Hodgkin's lymphoma of the stomach: three radical modalities of treatment in 75 patients. *Ann Surg Oncol*.3:277-284.
- 86- **Smith MR., (2006):** Non-Hodgkin's lymphoma. *Curr Probl Cancer*; 20:6–77.
- 87- **Song KW, Barnett MJ, Gascoyne RD, Horsman DE, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, et al., (2006):** Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. *Br J Haematol.*; 133:634–637.
- 88- **Stanojević G, Stojanović M, Jovanović M, Stojanović M, Jeremić M, Branko B, Ignjatović N, Katić VV., (2009):** [Primary colorectal lymphomas] *Vojnosanit Pregl.*;66:295–301.
- 89- **Steinbach G, Ford R, Globler G, et al., (2002):** Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled study. *Ann Intern Med*; 131:88–95.
- 90- **Stephens J, Smith J., (2001):** Treatment of primary gastric lymphoma and gastric mucosa-associated lymphoid tissue lymphoma. *J Am Coll Surg*; 187:312–20.
- 91- **Steven S and Jerard, (1997):** Human Anatomy & Physiology, Sixth Edition. Chap7, Pp: 712-735. Edited by Elaine N and Marieb J.Pa:Benjamin-Cummings.

- 92- ***Stolte M, Bayerdörffer E, Morgner A, Alpen B, Wundisch T, Thiede C, Neubauer A.(2002):*** Helicobacter and gastric MALT lymphoma. Gut; 50 (Suppl 3): 19-24.
- 93- ***Streubel B, Lamprecht A, Dierlamm J, Cerroni L, Stolte M, Ott G, Raderer M, Chott A., (2003):*** t(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood; 101: 2335-9.
- 94- ***Taal BG, Boot H, van Heerde P, et al., (2006):*** Primary non-Hodgkin lymphoma of the stomach: endoscopic pattern and prognosis in low versus high-grade malignancy in relation to the MALT concept. Gut39:556–61.
- 95- ***Thiede C, Morgner A, Alpen B, et al., (2004):*** What role does the eradication of Helicobacter pylori play in gastric MALT and gastric MALT lymphoma? Gastroenterology; 113:S61–4.
- 96- ***Uren AG, O'Rourke K, Aravind LA, Pisabarro MT, Seshagiri S, Koonin EV, Dixit VM., (2000):*** Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell; 6: 961-7.
- 97- ***Velasco M, Concepcion L, Jones D (2002):*** Primary gastric and intestinal lymphoma. In: Kelsen D, Daly J, Levin B et al, (eds): Gastrointestinal oncology principle and practice (1st ed) Philadelphia: Lipincott-Wilkins: 899-918.
- 98- ***Weisenburger D.D., and Armitage J.O., (2001):*** Mantle cell lymphoma: an entity comes of age. Blood 87: 4483-4494.
- 99- ***Wotherspoon A, Doglioni C, Isaacson P (1998):*** Low-grade gastric B-cell lymphoma of mucosa associated lymphoid tissue (MALT) a multifocal disease. Histopathology; 20:29-34.

- 100- ***Yamamoto S, Nakase H, Yamashita K, Matsuura M, Takada M, Kawanami C, Chiba T., (2010):*** Gastrointestinal follicular lymphoma: review of the literature. *J Gastroenterol*; 45:370–388.
- 101-***Zinzani PL, Magagnoli M, Pagliani G, Bendandi M, Gherlinzoni F, Merla E, et al., (1997):*** Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. *Haematologica*; 82: 305-308.
- 102-***Zucca E and Cavalli F (1996):*** Gut lymphomas. *Bailliere`s clinical Hematology*; 9(4): 727-741.